JP2024545253A5 - - Google Patents
Info
- Publication number
- JP2024545253A5 JP2024545253A5 JP2024536100A JP2024536100A JP2024545253A5 JP 2024545253 A5 JP2024545253 A5 JP 2024545253A5 JP 2024536100 A JP2024536100 A JP 2024536100A JP 2024536100 A JP2024536100 A JP 2024536100A JP 2024545253 A5 JP2024545253 A5 JP 2024545253A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide according
- antigen protein
- virus
- polynucleotide
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265634P | 2021-12-17 | 2021-12-17 | |
| US63/265,634 | 2021-12-17 | ||
| US202263393400P | 2022-07-29 | 2022-07-29 | |
| US63/393,400 | 2022-07-29 | ||
| PCT/JP2022/046430 WO2023113016A1 (en) | 2021-12-17 | 2022-12-16 | Efficient vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545253A JP2024545253A (ja) | 2024-12-05 |
| JP2024545253A5 true JP2024545253A5 (https=) | 2025-04-18 |
Family
ID=86774453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536100A Pending JP2024545253A (ja) | 2021-12-17 | 2022-12-16 | 効率的なワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230201333A1 (https=) |
| EP (1) | EP4448770A4 (https=) |
| JP (1) | JP2024545253A (https=) |
| TW (1) | TW202338090A (https=) |
| WO (1) | WO2023113016A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025121971A1 (ko) * | 2023-12-07 | 2025-06-12 | 기초과학연구원 | 자가 증폭 rna를 포함하는 바이러스 유사 입자 제조를 위한 알파 바이러스 기반 벡터 시스템 |
| WO2025263616A1 (en) * | 2024-06-21 | 2025-12-26 | Vlp Therapeutics Japan, Inc. | Efficient vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2327835C (en) * | 1998-04-08 | 2010-09-21 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| US20030040498A1 (en) * | 2001-03-14 | 2003-02-27 | Ansardi David Calvert | Oncolytic RNA replicons |
| EP2848692B1 (en) * | 2004-05-21 | 2017-08-16 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| CA2766907A1 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| SG11202005792RA (en) * | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| CA3167611A1 (en) * | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| TWI891771B (zh) * | 2020-04-17 | 2025-08-01 | 美商Ｖｌｐ醫療股份有限公司 | 冠狀病毒疫苗 |
| WO2021255270A1 (en) * | 2020-06-19 | 2021-12-23 | Ziphius Vaccines | Self-amplifying sars-cov-2 rna vaccine |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
| CN111961138B (zh) * | 2020-10-20 | 2021-03-30 | 苏州茂行生物科技有限公司 | 疫苗融合蛋白 |
-
2022
- 2022-12-16 EP EP22907538.7A patent/EP4448770A4/en active Pending
- 2022-12-16 WO PCT/JP2022/046430 patent/WO2023113016A1/en not_active Ceased
- 2022-12-16 JP JP2024536100A patent/JP2024545253A/ja active Pending
- 2022-12-16 US US18/067,358 patent/US20230201333A1/en active Pending
- 2022-12-16 TW TW111148556A patent/TW202338090A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018186815A5 (https=) | ||
| JP2023519173A5 (https=) | ||
| JP2024545253A5 (https=) | ||
| Lundstrom | Alphavirus vectors for vaccine production and gene therapy | |
| US10570416B2 (en) | TC-83-derived alphavirus vectors, particles and methods | |
| US8158418B2 (en) | Chimeric alphavirus replicon particles | |
| JP5016305B2 (ja) | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 | |
| US7572453B2 (en) | Chimeric alphavirus replicon particles | |
| JP2023134488A5 (https=) | ||
| JP2023551982A5 (https=) | ||
| JP2015527296A5 (https=) | ||
| JP2005502355A5 (https=) | ||
| IL145702A (en) | Method of preparing infectious influenza viruses in the absence of a helper virus | |
| AU2002303330A1 (en) | Chimeric alphavirus replicon particles | |
| WO2001083794A3 (en) | Dna transfection system for the generation of infectious influenza virus | |
| JP2003516148A5 (https=) | ||
| JP2023545009A5 (https=) | ||
| JP2023536570A5 (https=) | ||
| EP2331557B1 (en) | Alphavirus packaging cell lines | |
| Lundstrom | The Potential of RNA Vaccines for Infectious Diseases and COVID-19 | |
| CA2430115A1 (en) | Recombinant rsv virus expression systems and vaccines | |
| JP2007516721A5 (https=) | ||
| JP2018537103A5 (https=) | ||
| JP2007512827A (ja) | αウイルス由来ベクターを含むウイルス粒子、ならびに前記ウイルス粒子の調製方法 | |
| Li et al. | Application of self-amplifying mRNA technology in the development of infectious disease vaccines |